Clinical Education
Why Melasma Requires a Conservative Energy Strategy
Melasma is inflammation-sensitive and recurrence-prone, so aggressive energy-based treatment risks PIH and rebound. The evidence base anchors on gentler, repeated 1064 nm picosecond treatment framed as management, not one-time clearance.
Melasma punishes force
Most corrective laser categories reward decisiveness: treat the target thoroughly, let the skin remodel, book the next stage. Melasma inverts that logic.
The condition sits on easily-provoked pigment biology — melanocytes that respond to heat, inflammation, hormones, and light by producing more pigment. Treat it like a tattoo and the skin can answer with post-inflammatory hyperpigmentation (PIH) and rebound darkening. The patient sees their melasma “come back worse”; the practice sees a hard conversation.
That is why experienced providers treat melasma as a condition to be managed with restraint, not cleared with force.
The evidence pattern says the same thing
The randomized evidence that shows melasma actually improving is not built on maximal treatment. A 2023 systematic review and meta-analysis of randomized trials found significant MASI/mMASI improvement in the 1064 nm picosecond subgroup, with no significant side effects reported — while the 755 nm subgroup did not significantly outperform topical depigmenting agents and reported PIH. View the PubMed record.
Two lessons sit inside that result:
Wavelength is the first act of restraint. 1064 nm’s lower relative absorption by epidermal melanin means less energy captured at the surface, where PIH begins — the foundation of the 1064-first planning logic.
Improvement arrived through repeated, tolerable sessions. The successful protocols are courses of care, not single dramatic events.
Strategy, not settings
None of this is a parameter recipe — exact technique, spacing, and intensity remain provider decisions for the individual patient. The strategic pattern, though, is consistent:
Choose the wavelength that spares the epidermis. Do not ask intensity to compensate for the wrong optical starting point.
Plan a course, not an event. Judge results across repeated sessions, and set patient expectations the same way.
Respect the recurrence. Melasma is recurrence-prone. Honest positioning — improvement and management, never permanent clearance — protects the patient relationship and the practice’s credibility. The vascular component of melasma is one more reason a single “blast the pigment” model was never the right frame.
Conservative strategy needs capable equipment
A conservative plan is a choice made from headroom. The platform should hold more capability than any one plan uses — so the provider can select a gentle mode deliberately rather than run a limited system at its ceiling.
That is the architecture argument for Pro 1 Pico: a 1064 nm foundation with multiple ways to use it — picosecond, PTP dual-pulse, long-pulse — plus 532 nm where it belongs (see 1064 nm vs 532 nm), inside a platform whose business case never rested on melasma alone.
And commercially, a management condition is not a consolation prize. It is a recurring patient relationship — courses, maintenance, and adjacent concerns over time — which is exactly the utilization pattern the Pro 1 Pico revenue model is built to capture.
Explore Pro 1 Pico → Request Pricing →
Continue reading
- Melasma Treatment: Why Wavelength and Strategy Matter
- Melasma in Darker Skin: Why 1064 nm Matters
- The Vascular Component of Melasma
Treatment suitability and parameters remain provider-directed. Results vary, and melasma may recur.
Technologies covered
Related devices
Related applications
FAQs
Why can aggressive laser treatment make melasma worse?
Melasma sits on top of easily-provoked pigment biology. Treatment intense enough to inflame the skin can trigger post-inflammatory hyperpigmentation and rebound darkening — the visible result reads as the melasma 'coming back worse.' That risk is highest in the pigment-prone skin where melasma is most common.
Does the clinical evidence support a gentler approach?
The randomized melasma evidence that shows significant improvement anchors on 1064 nm picosecond treatment delivered over repeated sessions, with no significant side effects reported in that subgroup — while the 755 nm subgroup reported PIH. The pattern favors wavelength-appropriate, repeated, conservative treatment.
How many sessions does melasma treatment take?
Published protocols are built on a course of repeated treatments rather than a single session, with the exact number, spacing, and technique determined by the provider for the individual patient. Melasma management also typically continues beyond an initial course because the condition is recurrence-prone.
Does a conservative strategy mean weaker equipment is fine?
The opposite. A conservative strategy is a choice made from headroom — the platform should offer more capability than a given plan uses, plus the wavelength foundation and mode flexibility to adjust the plan. What it rules out is depending on intensity to compensate for the wrong wavelength.
What does this mean for the business side of melasma?
A management condition creates a recurring patient relationship: treatment courses, maintenance visits, and adjacent concerns over time. That favors platforms whose value is judged on repeat utilization across a treatment menu, not on a single dramatic session.